| Description |
HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research[1].
|
| Related Catalog |
|
| In Vitro |
HX630 (0.1-10 μM, 96 h) 可以剂量依赖性的抑制细胞增殖诱导 AtT20 细胞凋亡[1]。 Cell Viability Assay[1] Cell Line: AtT20 cells Concentration: 0.1, 1, 5, 10 μM Incubation Time: 96 h Result: Significantly inhibited AtT20 cell proliferation at 10 μM. Decreased Pomc mRNA expression and ACTH secretion in a dose-dependent manner.
|
| In Vivo |
HX630（5 mg/kg，腹腔注射，每周 3 次，持续 3 周）在感染了AtT20 细胞的 BALB/c-nu 小鼠模型中，可以减少肿瘤的生长[1]。 Animal Model: Female BALB/c-nu mice (nu/nu) with AtT20 cells[1] Dosage: 5 mg/kg Administration: i.p., 3 times a week for 3 weeks Result: Significantly reduced tumor volume and Pomc mRNA expression in tumor cells, but body weight and plasma ACTH levels were not significantly different.
|
| References |
[1]. Akiko Saito-Hakoda, et al. Effects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc Expression. PLoS One. 2015 Dec 29;10(12):e0141960.
|
